For Immediate Release
Chicago, IL –July 23, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth UNH, Citigroup C, Honeywell HON, IBM IBM and Amgen AMGN.
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for UnitedHealth, Citigroup and Honeywell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth, Citigroup and Honeywell. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
UnitedHealth’s shares have gained +2% in the past year, outperforming the Zacks Medical Insurance industry, which has increased +1.7% over the same period. UnitedHealth Group’s earnings surpassed expectations by 4%, and were up 15% year over year. The Zacks analyst thinks the company stands apart in the industry by virtue of healthcare services, technology and innovations offered by its unit Optum.
Numerous acquisitions made by the company have broadened its business profile and provide benefits of diversification. Its solid balance sheet and consistent cash flow generation has enabled investment in business which will drive long term growth. Also, capital management through dividend payments and share buybacks is another positive.
However, slowdown of growth in international operations and underperformance of the Medicaid business are some concerns. An increase in leverage and substantial interest burden raises financial risk.
(You can read the full research report on UnitedHealth here >>>).
Shares of Citigroup have outperformed the Zacks Major Regional Banks industry in the past six months (+14.3% vs. +3.3%). The Zacks analyst thinks the company has an impressive earnings surprise history, beating expectations in all the trailing four quarters.
The company’s second-quarter 2019 results reflected expense control and higher revenues driven by consumer banking. However, lower fixed income, investment banking and equity market revenues amid challenging trading environment are acting as drags on the stock. Citigroup’s restructuring and streamlining efforts, along with strategic investments in core business, bode well for the long term.
Also, the company’s declining costs base supports its bottom-line improvement. Steady capital-deployment activities of the company are also commendable. However, pending litigation issues might keep legal expenses elevated.
(You can read the full research report on Citigroup here >>>).
Honeywell’s shares have outperformed the Zacks Diversified Operations industry in the past three months, gaining +0.4% vs. a -3.4% decline. In second-quarter 2019, Honeywell's earnings grew 8.8% year over year and exceeded expectations by about 1%.
The Zacks analyst thinks strength in its commercial aerospace, warehouse and process automation’s businesses as well as solid demand for its commercial fire and security products will boost revenues in the quarters ahead. Stronger sales volumes, increased productivity and ongoing commercial effectiveness actions will improve near-term profitability.
For 2019, Honeywell raised earnings guidance from $7.90-$8.15 to $7.95-$8.15 per share. However, the stock looks overvalued compared to the industry for the past three-month period. Also, the company is experiencing softness in its productivity products business.
(You can read the full research report on Honeywell here >>>).
Other noteworthy reports we are featuring today include IBM and Amgen.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM) : Free Stock Analysis Report
Citigroup Inc. (C) : Free Stock Analysis Report
Honeywell International Inc. (HON) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research